Previous Close | 2.3800 |
Open | 2.4600 |
Bid | 2.3500 x 600 |
Ask | 2.4100 x 800 |
Day's Range | 2.3300 - 2.4600 |
52 Week Range | 1.2100 - 3.0800 |
Volume | |
Avg. Volume | 974,183 |
Market Cap | 440.038M |
Beta (5Y Monthly) | 1.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1700 |
Earnings Date | Aug 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.40 |
CONCORD, Calif., July 18, 2024--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
CONCORD, Calif., July 02, 2024--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier th
CONCORD, Calif., June 21, 2024--Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27. Transfusion medicine experts and professionals from around the world attend the ISBT Congress.